I-Mab Revenue 2011-2026 | IMAB

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue I-Mab

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	88 M	1.54 B	30 M	53.8 M	11.6 M	-	-	-	-	-	-

All numbers in CNY currency

Indicator range from annual reports

Maximum	Minimum	Average
1.54 B	11.6 M	345 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	16.6 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	75.1 M	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	7.21 B	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	720 M	$ 229.25	0.44 %	$ 5 B	Danmark
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
ANI Pharmaceuticals ANIP	614 M	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	75.4 M	$ 1.41	2.17 %	$ 375 M	Britain
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	2.01 M	$ 1.51	48.04 %	$ 17 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
BioMarin Pharmaceutical BMRN	3.22 B	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	277 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	41 K	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	482 M	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	36.8 B	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	77.1 M	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	48.2 B	$ 59.6	-2.45 %	$ 121 B	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	330 M	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	451 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	351 M	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Cellectis S.A. CLLS	72.9 M	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	9.89 B	$ 177.34	-3.5 %	$ 26 B	USA
Axon Enterprise AXON	2.08 B	$ 412.81	-2.54 %	$ 31.3 B	USA